Page last updated: 2024-12-07
n-dodecanoylglutamic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-dodecanoylglutamic acid: RN refers to (DL)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 93133 |
| SCHEMBL ID | 55274 |
| MeSH ID | M0226473 |
Synonyms (39)
| Synonym |
|---|
| BB 0256762 |
| AKOS015839845 |
| 3397-65-7 |
| sdglu |
| n-dodecanoylglutamic acid |
| n-dodecanoyl-l-glutamic acid |
| (2s)-2-(dodecanoylamino)pentanedioic acid |
| A6010 |
| n-lauroylglutamic acid |
| dl-glutamic acid, n-(1-oxododecyl)- |
| n-lauroyl-l-glutamic acid |
| (s)-2-dodecanamidopentanedioic acid |
| lauroyl glutamic acid |
| unii-mt62245356 |
| nsc 522180 |
| n-(1-oxododecyl)-l-glutamic acid |
| einecs 222-261-1 |
| l-glutamic acid, n-(1-oxododecyl)- |
| mt62245356 , |
| AKOS015901453 |
| nalpha-lauroyl-l-glutamic acid |
| AVBJHQDHVYGQLS-AWEZNQCLSA-N |
| lauroyl-l-glutamic acid |
| SCHEMBL55274 |
| lauroylglutamic acid |
| glutamic acid, n-lauroyl-, l- |
| lauroyl glutamic acid [who-dd] |
| glutamic acid, n-lauroyl- |
| lauroyl glutamic acid [inci] |
| amisoft la |
| c17h31no5 |
| DTXSID7074820 |
| mfcd06410798 |
| n-dodecanoyl-l-glu |
| dodecanoyl-l-glutamic acid |
| CS-0111611 |
| DS-16193 |
| C74746 |
| Q27284219 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.30) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||